Hematological cancer in 2011: New therapeutic targets and treatment strategies.
2011 saw improvements in our understanding of B-cell malignancies: insights into the genomic basis of chronic lymphocytic leukemia were achieved; reduced treatment intensity caused fewer toxic effects in early-stage Hodgkin lymphoma; first-line rituximab maintenance therapy improved outcome in follicular lymphoma; and selected patients with diffuse large-cell lymphoma benefited from the addition of bortezomib.
Department of Internal Medicine I and Center for Integrated Oncology Köln-Bonn, University of Cologne, Joseph-Stelzmann-Straße. 9, 50924 Cologne, Germany.
Paula
P
Cramer
Michael
M
Hallek
D002986:Clinical Trials as Topic; D019337:Hematologic Neoplasms / Q000175:diagnosis* / Q000628:therapy*; D049674:History, 21st Century; D006801:Humans; D058990:Molecular Targeted Therapy